Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CLNN | Common Stock | Purchase | $84.5K | +106K | $0.80 | 106K | Jun 16, 2023 | By LLC | F1 | |
holding | CLNN | Common Stock | 68.7K | Jun 16, 2023 | Direct | ||||||
holding | CLNN | Common Stock | 2.15M | Jun 16, 2023 | By LLC | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CLNN | Warrants (Right to buy) | Award | +106K | 106K | Jun 16, 2023 | Common Stock | 106K | $1.50 | Direct | F3, F4 | |||
transaction | CLNN | Warrants (Right to buy) | Award | +106K | 106K | Jun 16, 2023 | Common Stock | 106K | $1.10 | Direct | F3, F5 |
Id | Content |
---|---|
F1 | The securities are owned by Kensington CI II, LLC. Mr. Gay is a manager of and owns a minority interest in Kensington CI II, LLC. The shares owned by Kensington CI II, LLC may be deemed to be beneficially owned by Mr. Gay. Mr. Gay disclaims all shares owned by Kensington CI II, LLC for which he does not have a pecuniary or profits interest. |
F2 | The securities are beneficially owned by KSV Gold, LLC. Mr. Gay is a member of KSV Gold, LLC's management team. The shares beneficially owned by KSV Gold, LLC may also be deemed to be beneficially owned by Mr. Gay. However, Mr. Gay has no control over how the shares owned by KSV Gold, LLC are voted and disclaims all shares for which he does not have a pecuniary or profits interest. |
F3 | The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant. |
F4 | Kensington CI II, LLC purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche B Warrant is for 105,625 shares of Common Stock of Clene Inc. at an exercise price of $1.50 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc. The shares owned by Kensington CI II, LLC may be deemed to be beneficially owned by Mr. Gay. Mr. Gay disclaims all shares owned by Kensington CI II, LLC for which he does not have a pecuniary or profits interest. |
F5 | Kensington CI II, LLC purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche A Warrant is for 105,625 shares of Common Stock of Clene Inc. at an exercise price of $1.10 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc. The shares owned by Kensington CI II, LLC may be deemed to be beneficially owned by Mr. Gay. Mr. Gay disclaims all shares owned by Kensington CI II, LLC for which he does not have a pecuniary or profits interest. |